Impact of Arterial Remodeling of Intermediate Coronary Lesions on Long-Term Clinical Outcomes in Patients with Stable Coronary Artery Disease: An Intravascular Ultrasound Study

Table 1

Baseline characteristics of the study group.

	IR (n = 72)	NR (n = 77)	PR (n = 63)	value
Age, years	63.68 ± 10.93	65.43 ± 8.94	62.67 ± 8.94	0.238
Male, n (%)	42 (58.33)	38 (49.35)	45 (71.43)	0.030
Hypertension, n (%)	47 (65.28)	54 (70.13)	35 (55.56)	0.196
Hypercholesterolemia, n (%)	12 (16.67)	10 (12.99)	9 (14.29)	0.814
Diabetes, n (%)	23 (31.94)	22 (28.57)	24 (38.10)	0.484
Current smoker, n (%)	27 (37.50)	19 (24.68)	27 (42.86)	0.063
Prior PCI history, n (%)	8 (11.11)	11 (14.29)	7 (11.11)	0.795
Prior CABG history, n (%)	1 (1.39)	2 (2.60)	1 (1.59)	0.845
Left ventricular eject fraction (%)	62.10 ± 3.11	62.28 ± 2.65	61.66 ± 3.44	0.536
Prior MI	2 (2.78)	1 (1.30)	1 (1.59)	0.785
BMI	24.94 ± 1.32	24.65 ± 1.26	25.19 ± 1.47	0.071
Multivessel disease, n (%)	49 (63.64)	39 (54.17)	38 (60.32)	0.493
Laboratory
Creatinine (μmol/l)	67.17 ± 16.65	72.49 ± 17.48	76.96 ± 21.31	0.015
LDL-C (mmol/l)	2.72 ± 0.96	2.71 ± 0.93	2.54 ± 1.03	0.560
TG (mmol/l)	1.64 ± 1.13	1.60 ± 0.92	1.51 ± 0.94	0.786
HBA1c (%)	6.28 ± 1.04	6.18 ± 0.84	6.69 ± 1.36	0.044
Medications at discharge
Aspirin, n (%)	58 (80.56)	54 (70.13)	46 (73.02)	0.327
Clopidogrel, n (%)	19 (26.39)	30 (38.96)	23 (36.51)	0.237
Statin, n (%)	63 (87.50)	70 (90.91)	54 (85.71)	0.621
β-Blocker, n (%)	41 (56.94)	36 (46.75)	34 (53.97)	0.440
ACEI/ARB, n (%)	26 (36.11)	28 (36.36)	17 (26.98)	0.426
Insulin, n (%)	3 (4.17)	1 (1.30)	5 (7.94)	0.153
Oral hypoglycemic agents, n (%)	11 (15.28)	11 (14.29)	17 (26.98)	0.109

ACEI, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; HBA1c, hemoglobin A1c; IR, intermediate remodeling; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NR, negative remodeling; PCI, percutaneous coronary intervention; PR, positive remodeling; TG, triglyceride.